Establishment of latent HIV-1 reservoirs: what do we really know?

Jef Vanhamel, Anne Bruggemans and Zeger Debyser*

Center for Molecular Medicine, University of Leuven, Leuven, Belgium

Abstract

Despite our ability to suppress HIV-1 replication indefinitely in people on optimal combined antiretroviral therapy (cART), HIV-1 persists as a stably integrated and replication-competent provirus in a heterogeneous collection of long-lived cells (often referred to as ‘latent reservoirs’) in all individuals on treatment. Reactivation of these latent proviruses is believed to be responsible for the rebound viremia that can be seen in nearly all people following treatment cessation. Hence, the persistence of HIV-1 in latent reservoirs remains one of the greatest challenges in current HIV cure research. Latent HIV-1 reservoirs are established early during the acute phase of the infection, possibly before the virus appears in the systemic circulation. As well as the issue of timing, we review the proposed hypotheses on the mechanisms by which this latent state is believed to be established early in the course of the infection and the effect of early initiation of cART on the size and stability of these reservoirs.

We conclude that prevention of the establishment of latent HIV-1 reservoirs by even extremely early initiation of cART proves to be practically impossible. However, early treatment initiation remains one of the crucial interventions needed to achieve the ultimate goal of a functional cure for HIV-1 infection because of its ability to reduce the overall size of HIV-1 reservoirs. Together with other interventions, early cART initiation may thus eventually lead to a state of better control over the residual amount of virus in the body, allowing people to stay off treatment for prolonged periods of time.

Introduction

The implementation of combination antiretroviral therapy (cART) has led to a dramatic improvement in outcomes for people living with HIV, turning a previously life-threatening illness into a chronic condition [1].

Despite its great success, it remains difficult to provide this revolutionary therapy to all people living with HIV, especially to those in resource-limited settings. This is particularly problematic given the need for strict therapeutic adherence. Taken together with the possibility of drug toxicity, drug–drug interactions, persistent immune dysfunction and ongoing low-grade inflammation in people on therapy, there is a growing interest in finding a cure for HIV rather than control of HIV replication [2]. The report of the Berlin patient, who is considered to be cured, and some cases of long-lasting remission have strongly fuelled the ongoing research in this field [3–6].

Indeed, cART is very effective in suppressing plasma virus levels to below the limit of detection of commercial assays (20–50 copies HIV-1 RNA/ml), yet fails to be curative as viral loads rebound quickly upon cART cessation, typically within 2 weeks. This makes lifelong treatment an absolute necessity and the current standard of treatment for every individual living with HIV [7,8]. The main reason for viraemic rebound after cART cessation is believed to be the presence of stable reservoirs of HIV-1 provirus in resting CD4 T cells, even in patients on long-term cART [9–11].

The main focus of recent research has been towards eliminating viral reservoirs via a strategy called the ‘shock and kill’ [12]. Briefly, latent proviruses are reactivated with latency-reversing agents, restarting viral replication in the infected cell. This should lead to the elimination of these cells through viral cytopathic effects or by immune-mediated killing as they now express viral proteins. So far, attempts to purge the reservoir in this fashion have been largely unsuccessful, since both parts of the strategy, shock and kill, still need optimising [13]. At the same time, other creative strategies (e.g. ‘block and lock’, which aims to create a permanent nonproductive state of infection) are also being investigated [14].

In order to optimise these approaches and to create new strategies to target viral reservoirs of HIV-1, a more thorough understanding of their biology, composition, distribution and dynamics will be of the utmost importance. We review the evidence on the establishment of latent HIV-1 reservoirs during the acute phase of the infection.

Background

HIV reservoirs

The term ‘latency’ in virology usually refers to a nonproductive state of infection of a pool of cells that are transcriptionally silent, but retain the capacity to produce infectious virus particles upon stimulation [15]. This is different from ‘clinical latency’, a term formerly used to describe the clinically asymptomatic phase following the acute infection with HIV-1 and before the development of AIDS.

A reservoir is defined as ‘a cell type or anatomical site in which a replication-competent form of virus accumulates and persists’ [16], in spite of long periods of cART-suppressed viremia [15]. Since various types of cells in different anatomical locations can fulfill these criteria, it is more accurate to consider HIV reservoirs in a plural form. Of note, this definition does not include most integrated HIV-1 genomes, as many are defective [17]. Evidence seems to indicate that even on suppressive cART there may be some ongoing active viral replication, in selected patients and/or in certain sanctuary sites [15]. These reservoirs may significantly contribute to the problem of viral persistence on therapy, but they do not qualify as ‘latent’ reservoirs in the stricter sense. As such, we will not discuss them in great detail.

It should also be noted that, since the focus of our review was on the timing of reservoir establishment, we did not perform a...
systematic review of the literature on cellular and anatomical reservoirs and sanctuary sites for HIV infection. When considering HIV infection, timing and location of reservoir formation cannot be separated, hence, we will provide a short overview of the current knowledge on cellular and anatomical HIV reservoirs (including possible sanctuary sites). For more extensive reviews we refer to [18–22].

**Cellular reservoirs**

HIV primarily infects cells of the immune system and in particular CD4 T cells. They also remain the best characterised reservoirs for HIV-1 in virally suppressed patients on cART [18–20]. T cells are classified according to their differentiation and memory status, or their effector functions, based on the expression of cell surface markers [18,19,23]. Naïve CD4 T cells are produced in the bone marrow and move to the thymus where they undergo antigenic selection. After stimulation, these cells proliferate and differentiate into active, specialised effector cells, including helper T cells (TH1, TH2, TH17 and TH9), follicular T helper cells (TFH) and regulatory T cells [18,23]. These activated CD4 T cells are the preferential targets for productive HIV-1 infection but they have short lifespans owing to cytopathic effects of the virus or cytotoxic T lymphocyte-mediated killing [24]. However, some effector cells can revert to a resting state and differentiate into long-lived memory CD4 T cells [25]. Different types of memory CD4 T cells exist: stem cell memory (TSCM), central memory (TCM), transitional memory (TTM), effector memory (TEM), migratory memory (TMM), tissue resident memory (TRM) and terminally differentiated (TTD) cells [18,19,23]. Studies have shown that the distinct CD4 memory T cell subsets are infected to a different extent by latent HIV-1 and may support viral persistence through various mechanisms [25,26]. Central memory CD4 T cells are still considered to be the most important reservoir of latent HIV [18,19]. Interestingly, a skewed distribution of HIV-1 reservoirs from the long-lived TCM compartment towards shorter-lived populations of TTM and TEM seems to be important for natural control of the virus, as can be seen in both ‘elite-controllers’ (EC) and in ‘post-treatment controllers’ (PTC) [6,27]. Early cART initiation seems to protect the frequency of infection of all memory T cell subsets [28–30], with one study showing a relative protection of the TCM subset [31], although another subsequent study failed to replicate these findings and instead found a higher contribution of memory stem cells and central memory T cells to the latent reservoir [30]. It has therefore not been consistently established whether the TCM subset would be more protected than others by early treatment. Even haematopoietic precursor cells may contribute to the latent reservoirs, although results are conflicting [32,33].

Other immune cells have been implicated as reservoirs as well, especially myeloid cells. Macrophages are a known target for HIV infection [34], but their role as a reservoir remains debated [18–22,35]. Macrophages are not killed by viral cytopathic effects in vitro, which would make them a likely reservoir [35,36]. However, studies on HIV infection and latency in macrophages have been complicated by the diversity of these cells. Monocyte-derived macrophages appear in tissues following a local injury and can be replenished from the blood compartment, whereas tissue resident macrophages are established during fetal development [37]. They are maintained independently and are highly specialised per organ (into Kupfer cells, alveolar macrophages, intestinal macrophages, microglia cells etc.) [37]. Each subset of TRMs has a different susceptibility to HIV infection. Macrophages in the gut-associated lymphoid tissue (GALT) appear to be quite resistant to infection, except in the rectum, whereas alveolar macrophages seem relatively permissive [38–41].

Dendritic cells are a heterogeneous group of antigen-presenting cells, some with lymphoid and some with myeloid origin, with different features depending on their anatomical location [42]. They are susceptible to HIV infection in vitro, but appear less so than CD4 T cells in vivo. Still, dendritic cells are thought to aid the dissemination of HIV by sequestering intact virions and presenting them to T cells, thus infecting them [43]. Follicular dendritic cells in B follicles actually derive from perivascular precursors and may contribute to the reservoir in a different way; they may carry a stable pool of HIV-1 virions on their surface without being infected [44,45]. Finally, other cell types such as epithelial cells, fibrocytes and astrocytes are sometimes implicated as reservoirs, although these claims still need to be further investigated [19–22].

**Anatomical HIV reservoirs**

After HIV enters the body and local replication occurs at the site of entry, HIV quickly disseminates to the lymph nodes (within days) and later on (within weeks) to the bloodstream [46]. At this point, the virus spreads throughout the entire body as individual viroins, by the transport of infected immune cells and by cell-to-cell transmission [20,47]. Indeed HIV-infected cells have been found in the brain (and cerebrospinal fluid), the lungs, kidneys, liver, adipose tissue, in the gastrointestinal tract, the male and female genitourinary systems and bone marrow [20,22]. However, the lymphoid tissues (spleen, thymus, lymph nodes, GALT) are the most important sites of viral replication during active infection, and HIV DNA can still be detected in the lymph nodes after years of cART [22]. Within these organs, HIV is usually found within T cells and macrophages, but also in more organ-specific cell types (such as epithelial cells, microglia, astrocytes and podocytes) [19,20,22]. The contribution of all these anatomical compartments as latent reservoirs is still debated.

Overall, research on HIV reservoirs is still in its infancy. There is much data from in vitro, in vivo and animal models but as yet no gold standard to determine the size of the latent reservoir. Patient populations are highly heterogeneous (virus strain, route of transmission, ethnicity, lifestyle, timing of cART, duration and type of treatment, rate of suppression, etc.). All of these factors may influence HIV reservoirs and confound experimental studies.

**Methods**

We conducted a systematic literature search of all English-language articles published between January 1997 and November 2017 using MEDLINE (PubMed). Where available, medical subject headings (MeSH) were used as search terms and included: HIV-1 and virus latency. Additional search terms consisted of reservoir, latent, persistence, establishment, generation, formation and seeding. A total of 301 articles was found using the above search terms. Of these, 79 relevant articles related to HIV-1 latency establishment were collected and reviewed, with no limitation of study design. Additional studies (commonly referenced and/or older and more recent articles of significance) were selected from bibliographies and references listed in the primary resources.

**Results**

Mechanisms of latent HIV-1 reservoir establishment

In general, when exploring the literature, there are two main models that can be distinguished to explain latent memory cell infection: pre-activation and post-activation latency.
In the pre-activation model of latency, resting CD4 memory T cells are directly infected by HIV-1 before they are re-activated by stimuli from the environment. This process of direct resting cell infection is usually considered very inefficient due to blocks at various points in the viral life cycle [48,49]. It therefore resolves mostly in non-integrated linear and cytoplasmic forms of the viral genome with a half-life of approximately 1–6 days, due to instability of the pre-integration complex (also called ‘pre-integration latency’) [50–52]. However, it has been shown that certain cytokines and chemokines from the tissue microenvironment have the ability to make these resting CD4 T cells more permissive to HIV-1 infection, resulting in integrated proviruses without inducing cell proliferation or upregulation of T cell activation markers in vitro [53–55]. It cannot, therefore, be entirely excluded that such mechanisms could also occur in vivo, as it has been previously shown that mucosal CD4 resting T cells can at least be productively infected by HIV-1 in vivo [56,57].

Alternatively, the post-activation model for latency establishment is derived from studying normal T cell biology. As previously described, a small subset of antigen-stimulated active CD4 T cells will return to a resting state, awaiting activation upon re-encounter of the same antigen in the future, hence fulfilling their memory potential [58]. In theory, activated CD4 T cells can become infected with HIV-1 in the process of transitioning back to this resting state, allowing integration of the proviral genome in a host cell lacking favorable conditions for optimal viral gene expression, hence escaping rapid destruction of the infected T cell [10,52,59]. Evidence in support of this theory has come indirectly from in vitro models showing that HIV-1 is able to establish a latent infection in actively replicating T cells which, after being cultured with specific cytokines that induce a resting cell phenotype, are capable of producing active virus after stimulation with latency-reversing agents [54,60,61].

In the latter view, latency is considered as being merely an epiphenomenon of the activation status of the cell. Recent studies, however, show that T cell activation status and HIV-1 latency might not be as tightly coupled as previously thought. In this respect, Calvanez et al. have repeatedly shown that HIV-1 latency can be established directly in both activated and resting CD4 T cells, but with a different ratio of productive versus latent infection in both cell types [54,62]. This view gives rise to yet another possible model, whereby HIV-1 latency established in activated CD4 T cells shortly after entry confers a greater potential to survive and possibly return to a resting memory state, contributing to the long-lived latent reservoirs [54]. HIV-1 integration-site selection may play a role in the mechanisms of establishment of HIV-1 latency in these activated CD4 T cells. Indeed HIV-1 integration is not random but targeted towards active genes [63–67].

In vitro, the easy answer to this question would be ‘very early in the course of the infection’, at least before the symptomatic primary infection phase occurs and the available commercial diagnostic assays can confirm the diagnosis [50,87]. The initiation of cART before the establishment of latent HIV-1 reservoirs can prevent lifelong acquisition of HIV, as this is the principle behind post-exposure prophylaxis (PEP). This brings us to the vital question of how early reservoirs are seeded.

In most documented cases of children with perinatally acquired HIV-1 where cART is initiated within 30 hours of delivery, rebound viraemia occurs at some point after cART discontinuation. This seems to suggest indirectly that such an early seeding of viral reservoirs as seen in rhesus monkeys could also occur in humans [90–92]. However, the precise moment of infection could not be defined in these children and could have occurred in utero sometime before delivery.

It is particularly challenging to study the precise time at which reservoirs are established in humans because we cannot reliably detect the virus this early in the infection because our methods of detection mainly focus on the systemic viraemia phase. However, the possibility of the viral reservoirs being seeded during the mucosal eclipse phase of the infection calls for a better understanding of the early events after transmission of the virus. Much
of our current knowledge on this topic, comes from studies with a rhesus macaque model of SIV vaginal transmission by Haase et al. [57].

In these studies, it is shown that there is an eclipse phase of 1–3 days post-infection in which SIV DNA is detectable in the tissues at the portal site of entry before systemic viraemia occurs, with only few cells producing viral RNA representing progeny virus [93]. During these early stages of the infection, it appears that mostly resting CD4 T cells are productively infected by SIV at the portal site of entry. The same findings were observed in lymph node and tonsillar biopsies performed during the acute stage of HIV-1 infection in humans [56].

It is reasoned that because resting CD4 T cells greatly outnumber other potential target cells at the portal site of entry (here, the vaginal mucosa tissue) there is a greater possibility of virus encountering and infecting a resting cell until immune activation causes an influx of activated CD4 target cells to which the infection is later preferentially disseminated [94].

A more thorough characterisation of the activation state of these T cells productively infected by both SIV and HIV-1 in the early stage of the infection was performed by testing them for the activation markers CD25, CD71, CD30, CD38, CD134 and Ki67. Results showed that although cells with and without these activation markers were present, most cells were negative for each marker and could be categorised as resting [56].

Only a small fraction of the resting CD4 T cell population is infected during the first week after initial acquisition and a nearly 20-fold decrease in SIV RNA+ Ki67+ cells occurs between week 1 and 4 [94]. These findings suggest that an as yet undefined subpopulation of resting cells – possibly those in a slightly higher state of activation – can support productive infection. These cells are then either eliminated by viral cytopathic or host immune-effector mechanisms or can be activated. Alternatively, this decrease may reflect a conversion of the pool of initially productively infected cells to a state of latent infection [94]. Although it is very hard to provide direct evidence for these theories in humans, these studies show that the initial environment during the mucosal eclipse phase of the infection after sexual transmission of HIV-1, could potentially support the generation of a pool of latently infected resting CD4 T cells as early as a few days after initial acquisition. Whether these potentially latently infected cells have the ability to persist during the lifetime of the individual has not been clearly established.

The effect of timing of antiretroviral therapy initiation on size and stability of HIV-1 reservoirs

In spite of the previously described evidence for very early seeding of viral reservoirs during HIV infection, numerous studies have focused on the effect of early cART initiation on the size of the reservoirs and the possibility of achieving HIV remission when treatment is interrupted (post-treatment control).

It has been repeatedly shown that patients who start cART early during the acute HIV-1 infection phase (up to 6 months after acquisition) exhibit a lower overall reservoir size compared to those who start treatment later, for example during chronic infection [29,30,95–103]. Although these studies differ in patient characteristics, timing of cART initiation, total treatment duration and assays for reservoir size measurement, they all show a significant decrease in total HIV burden when cART is started early. It does appear that the earlier treatment is initiated during acute HIV-1 infection (AHI), the smaller the size of viral reservoirs after viral suppression, suggesting an escalation of HIV-1 reservoir seeding over time [96,100]. Moreover, Ananworanich et al. recently showed how during the acute stage of the infection in participants who received no treatment, total HIV-1 DNA in PBMCs peaked 2 weeks after enrollment, reaching a set point 2 weeks later with little change thereafter, while integrated HIV-1 DNA seemed to increase during untreated infection [101]. Very early cART could reduce the frequency of HIV-1 DNA-positive cells significantly, but this effect is probably less pronounced if treatment is initiated in later stages of the infection [100].

Even when cART is started during the acute infection phase of the disease, no further decay of the frequency of cells harbouring replication-competent HIV-1 to less than 0.5 cells per million could be achieved after long-term treatment, suggesting a subset of very early latently infected cells may persist indefinitely [97].

Starting treatment early may, however, be clinically relevant since high HIV-1 DNA levels are an independent predictor of disease progression [104,105] and pre-treatment total HIV-1 DNA and cell-associated HIV-1 RNA levels predicted time to viral rebound upon cART interruption in several studies [105,106]. Additionally, the inability to detect HIV-1 DNA does not seem to exclude the possibility of rebound plasma viraemia occurring at some point following treatment interruption [4,90,107].

Since lower overall reservoir size has been associated with increased time to viral rebound and early cART reduces the size of viral reservoirs, it has been hypothesised that early cART initiation

### Table 1. The Fiebig stage of primary HIV infection based on the emergence of a specific set of viral markers in the plasma of individuals who have acquired HIV. Classifications are based on a parametric Markov model

| Fiebig stage | Cumulative duration | HIV RNA | P24 antigen | Antibody (EIA) | Western blot |
|--------------|---------------------|---------|-------------|---------------|-------------|
|              | Days                | 95% confidence interval |          |               |             |
| I            | 5.0                 | 3.1–8.1 | +           |               |             |
| II           | 10.3                | 7.1–13.5| +           | +             |             |
| III          | 13.5                | 10.0–17.0| +           | +             | +           |
| IV           | 19.1                | 15.3–22.9| +           | +             | Indeterminate |
| V            | 88.6                | 47.4–129.8| +           | +             | + (p31 band negative) |
| VI           | Open ended          |         | +           | +             | + (p31 band positive) |

EIA: enzyme immunoassay; NS: not sensitive (refers to second generation not IgM-sensitive immunoassay); S: sensitive (refers to second generation IgM-sensitive immunoassay).
during AHI would delay viral rebound following treatment interruption. Yet cART initiated as early as Fiebig stage I (HIV-1 RNA+, p24+, HIV-1 IgM-; Table 1) did not result in a significantly longer time to viral rebound after treatment interruption when compared to cohorts with chronic HIV-1 infection. This suggests that early cART alone is not sufficient to induce HIV-1 remission and additional strategies to eliminate or control latently infected cells are required [88]. In contrast, long-term virological remission after interruption of cART has been achieved in three children with perinatally acquired HIV-1 who started treatment early [5,108,109], and several adults who started treatment during primary infection [6]. These cases do suggest that as well as the size of the reservoirs containing replication-competent proviruses, other factors such as the absence of ongoing replication and HIV-1 specific immunity are also of great importance in achieving durable HIV-1 remission [110].

**Discussion**

The focus of HIV research has shifted from ‘care’ to ‘cure’ with the aim of finding alternatives for the current standard of treatment: chronic suppressive antiretroviral therapy for the lifetime of the individual living with HIV [2].

Two distinct interpretations of a possible cure have been introduced. In the first, the ultimate goal remains the absolute and complete eradication of the virus from the body of individuals leading to permanent virological remission off treatment, an approach often referred to as a ‘sterilising cure’ [111]. It is believed that the Berlin patient was successfully cured using this approach. This case shows the great challenges that go with this strategy and raises questions concerning the safety, cost, feasibility and scalability of this approach [3]. This, combined with the inability to replicate this success story, has led to the second interpretation for cure, the aspiration for achieving a state of ‘sustained virologic remission’ or ‘functional cure’ in which individuals living with HIV can remain without treatment despite the objective persistence of replication-competent proviruses without rebound of plasma viremia [8]. As discussed above, early initiation of cART is likely to be one of the crucial steps in achieving long-lasting remission without treatment and the containment of the establishment of the viral reservoirs during the early stages of the infection appears to be a major contributing factor. Yet, some important questions remain unanswered.

How early does treatment need to be started? The findings of Buzon et al. suggest that initiating treatment as early as 6 months might not suffice [30]. Most evidence suggests that the earlier treatment is started, the better [100,101]. Using the Fiebig classification for AHI to define the point of treatment initiation [112], treatment during the earliest stages of the infection (e.g. Fiebig I and II) logically offers the most likely chance for an eventual stable HIV remission (Table 1). However, the exact window of opportunity for treatment initiation to achieve this goal remains to be elucidated. Most of the post-treatment controllers of the VISCONTI cohort [6] were treated in the later stages of AHI (Fiebig IV and V), highlighting the importance of additional parameters, such as immune control, that should be considered when plans for treatment interruption are being made. Thus, an accurate AHI staging system based upon a thorough characterisation of patients at time of treatment initiation (including factors such as HIV reservoir size, HIV specific immunity markers, HLA profile) to identify those more likely to benefit from HIV cure efforts is still lacking in the field.

Currently, as most widely available diagnostic assays are antibody-dependent and based on showing seroconversion, with most tests returning positive results 4–6 weeks after infection, there is also the practical problem of identifying individuals as early as a few days after infection. Very early detection of HIV-1 infection is possible using nucleic acid testing (NAT), directly identifying viral genetic material in the systemic circulation [113]. The use of these assays is limited owing to their cost, availability and the stigma or lack of awareness of risk factors that prevents individuals from seeking early testing. Additionally, symptoms of the acute retroviral syndrome do not occur in every individual and since symptoms are very non-specific, individuals do not always recognise them as signs of possible HIV acquisition [114].

Finally, the length of treatment required before interruption is defensible is unknown and we do not yet have the tools to determine the appropriate time for safe treatment interruption. For example, Chun et al. published a case report showing viral rebound 50 days after cART discontinuation in a person who initiated therapy during acute infection and remained on treatment for 10.5 years, despite undetectable levels of HIV-1 DNA in peripheral blood CD4 T cells or in sigmoid colon biopsies at the moment of treatment interruption [107]. Similarly, in the cases of the Mississippi child [5] and the Boston patients [4], investigators also failed to detect HIV-1 DNA, yet rebound viraemia eventually occurred in all of the individuals.

A small HIV-1 reservoir does seem to be important for achieving post-treatment viral control as a reduced reservoir size is a common finding in those PTC and EC identified to date. A critical shortcoming that remains, however, is a gold-standard method to measure intact replication-competent proviruses [115]. The current gold standard for measuring this form of the viral reservoir, the viral outgrowth assay (VOA), appears to underestimate the amount of replication-competent proviruses by 60-fold compared to direct detection methods of intact proviruses by sequence analysis [83]. There is a growing interest in finding more accurate detection methods [116]. Recent innovations include the Tat/rev induced limiting dilution assay (TILDA) [117] and the use of a reporter cell-based assay based upon the TZM-bl cell line [118], both of which have increased sensitivity, require less blood volume, are faster, less labour intensive and less expensive compared to the VOA. A noteworthy improvement to the PCR-based strategies is the development of the intact proviral DNA assay (IPDA) [119,120]. This digital droplet PCR assay detects intact, cell-associated, full-length genomic HIV DNA with increased sensitivity. Further validation, however, is needed to confirm the applicability of these assays in cART interruption studies.

A recent study by Henrich et al. reports the case of two extremely early HIV-1 diagnoses and subsequent treatment initiations, namely at the end of the eclipse phase and at the beginning of the start of Fiebig I, preceding the acute infection phase [121]. Despite the complete loss of detectable HIV-1 in blood, colorectal and ileal tissue, an excised inguinal lymph node, PBMCs, cerebrospinal fluid and a bone marrow biopsy in one individual following 32 weeks of continuous cART, rebound viraemia occurred 225 days following treatment interruption. This study highlights the extremely early seeding of HIV-1 reservoirs in humans, making future efforts aimed at the prevention of the establishment of viral reservoirs very likely to fail. On the other hand, it also provides an affirmation that increased time to viral rebound can be seen in those starting treatment very early. Future studies aimed at achieving a prolonged HIV remission state are therefore more likely to be successful if they focus on a combination strategy including early cART initiation, prolonged treatment duration, eliminating or silencing infected CD4 T cells and increasing the anti-HIV immune response [111,122].
Acknowledgements

Declarations of interests

The authors declare no conflict of interest.

References

1. Deeks SG, Lewin SR, Hivit DV. The end of AIDS: HIV infection as a chronic disease. Nature 2011; 473: 449–455.
2. Deeks SG, Lewin SR, Ross AL et al. International AIDS Society Global scientific strategy: towards an HIV cure. Nat Med 2016 22: 839–850.
3. Hutter G, Nowak DA, Mosser M et al. Long-term control of HIV by CCR5 Delta32/32 homozygous transplantation. N Engl J Med 2009; 360: 2185–2192.
4. Henrich T, Ju Z, Li ZJ et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 1999; 96: 1–6.
5. Richman DD, Margolis DM, Delaney M et al. Challenge of finding a cure for HIV infection. Science 1997; 278: 1295–1300.
6. Siliciano JD, Kajdas J, Finzi D et al. Evidence of a noncycling HIV-1 latent reservoir in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1997; 94: 13193–13197.
7. Finzi D, Hermankova M, Pieno T et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–1300.
8. Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727–728.
9. Archin NM, Liberty AL, Kashuba AD et al. Post-treatment HIV-1 controllers: rich in resting memory CD4 T cells and can induce T cell differentiation. Blood 2007; 110: 1726–1738.
10. Siliciano JD, Si Z, Li ZJ et al. Presence of an inducible HIV-1 latent reservoir even early in antiretroviral therapy. Annu Rev Immunol 2007; 25: 263–291.
11. Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727–728.
12. Archin NM, Liberty AL, Kashuba AD et al. Post-treatment HIV-1 controllers: rich in resting memory CD4 T cells and can induce T cell differentiation. Blood 2007; 110: 1726–1738.
13. Brander AM, Barosi G, Melino G et al. NF-kappaB activity favors active genes and local hotspots. EMBO J 2013; 32: 2415–2426.
14. Brenchley JM, Hill BJ, Ambrozak DR et al. T-cell subsets that harbor human immunodeficiency virus in vivo: implications for HIV pathogenesis. J Virol 2004; 78: 1160–1168.
15. Desouza B, Avettand-Fenoel V, Blanc C et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nongenotyped patients are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 2012; 54: 1495–1503.
16. Bachur C, Heret A, Avettand-Fenoel V et al. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One 2013; 8: e64219.
17. Josefsen L, von Stockenstrom S, Faris NR et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A 2013; 110: 4498–4505.
18. Buzon MJ, Martin-Gay E, Pereyra F et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1 infected CD4 T cells. J Virol 2014; 88: 10056–10065.
19. Heret A, Bachus-Souffren C, Avettand-Fenoel V et al. Combined ART started during acute HIV-1 infection affects central memory CD4+ T cells and can induce remission. J Antimicrob Chemother 2015; 70: 2108–2120.
20. Josefson L, Eriksson S, Smaila E et al. Hematopoietic progenitor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis 2012; 206: 28–34.
21. Durand CM, Ghauri G, Siliciano JD et al. HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD4+ hematopoietic progenitor cells and CD4+ CD27- resting T cells in patients on antiretroviral therapy. J Infect Dis 2012; 205: 1014–1018.
22. Gartner S, Markowitz P, Markovitz DM et al. The role of monomeric phagocytosis in HTLV-II/LAV infection. Science 1986; 233: 215–219.
23. Stevenson M. Role of myeloid cells in HIV-1-host interplay. J Neurovirol 2015; 21: 242–248.
24. Swengler S, Mann AM, Zhou J et al. Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog 2007; 3: 1281–1290.
25. Haldar M and Murphy KM. Origin, development, and homeostasis of tissue-resident macrophages. Immunol Rev 2014; 262: 25–35.
26. King DF, Siddiqui AA, Buffa V et al. Mucosal tissue dissemination and HIV subtype B acute envelope-expressing chimeric virus. J Virol 2013; 87: 890–898.
27. McElrath MJ, Smythe K, Randolph-Habecker J et al. Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus. J Acquir Immun Def Inf Syndr 2015; 692–811.
28. Malek KC, Band L, Kwan-Arata EM et al. Small alveolar macrophages are preferentially infected by HIV and exhibit impaired phagocytic function. Mucosal Immunol 2014; 7: 1116–1126.
29. Chen R, Meng G, Ochroch M et al. Stromal down-regulation of macrophage CD45/CCR5 expression and NF-kappaB activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog 2011; 7: e1002600.
30. Blanchereau J, Breire C, Faye C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767–811.
31. McDonald D, Wu L, Bohls SM et al. Recruitment of HIV and its receptors to dendritic cell–T cell junctions. Science 2003; 300: 1295–1297.
32. van der Reis K, de Graaf G, Human follicular dendritic cells: function, origin and development. Semin Immunol 2002; 14: 251–257.
33. Durand CM, Ghiaur G, Siliciano JD et al. Presence of an inducible HIV-1 latent reservoir even early in antiretroviral therapy. Annu Rev Immunol 2007; 25: 263–291.
34. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Nature 2009; 462: 25–33.
35. Stevenson M. Role of myeloid cells in HIV-1-host interplay. J Neurovirol 2015; 21: 242–248.
36. Swengler S, Mann AM, Zhou J et al. Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog 2007; 3: 1281–1290.
37. Haldar M and Murphy KM. Origin, development, and homeostasis of tissue-resident macrophages. Immunol Rev 2014; 262: 25–35.
38. King DF, Siddiqui AA, Buffa V et al. Mucosal tissue dispersion and HIV subtype B acute envelope-expressing chimeric virus. J Virol 2013; 87: 890–898.
98. Hoelqueloux V, Avettand-Fenoel V, Jacquot S et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal CD4+ T cell counts. J Clin Invest 2013; 123: 657–668.

99. Jain V, Hartogensis W, Bacchetti P et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208: 1202–1211.

100. Laarman M, Okon J, Essat A et al. Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clin Infect Dis 2015; 60: 1715–1721.

101. Ananworanich J, Chomont N, Eller LA et al. A hardwired HIV latency program. Elife 2014; 3: e03821.

102. Li JZ, Etemad B, Ahmed H et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016; 30: 343–353.

103. Chun TW, Justement JS, Murray D et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoirs: implications for eradication. AIDS 2010; 24: 2803–2808.

104. Frange P, Faye A, Avettand-Fenoel V et al. HIV-1 virological remission lasting more than 12 years after early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 2013; 6: e49–e54.

105. Violan A, Cottom M, Kuhn L et al. Viral and host characteristics of a child with perinatal HIV-1 infection followed for more than 12 years: a case report in the CHER trial. IAS Conference. Paris, France. Abstract TUPB0106LB.

106. Ananworanich J, Robb M. The transient HIV remission in the Mississippi baby: why is this good news? Journal of Virus Eradication 2014; 17: 19859.

107. Chun TW, Mair S, Faust AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol 2015; 16: 584–589.

108. Fiebig EW, Dörries K, Rawal BD et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17: 1871–1879.

109. Stammer S, Glynn SA, Klemann Sh et al. Detection of HIV-1 and HCV infections among injecting drug users by nucleic acid amplification testing. N Engl J Med 2004; 351: 760–768.

110. Robb ML, Eller LA, Klibaucia H et al. Prospective study of acute HIV-1 infection in adults in Eastern Africa and implications of dual infection. AIDS 2016; 30: 2120–2130.

111. Massanella M, Richard DD. Measuring the latent reservoir in vivo. J Clin Invest 2016; 126: 466–472.

112. Ananworanich J, Mellors J. How much HIV tails? The challenge of measuring replication competent HIV for HIV cure research. Elife 2015; 2: 788–789.

113. Procopio FA, Fromentin R, Kulpa DA et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. Elife 2015; 2: 789–794.

114. Sanyal A, Maillard RB, Rinaldo CR et al. Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells. Nat Med 2017; 23: 885–889.

115. Brunner KM, Murray AJ, Pollack RA et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med 2016; 22: 1043–1049.

116. Brunner KM, Pollack RA, Murray AJ et al. Rapid accumulation of defective proviruses complicates HIV-1 reservoir measurements. Conference on Retroviruses and Opportunistic Infections. 2016. Boston, MA, USA. Abstract 83.

117. Heinrich TJ, Hlatky H, Bacon O et al. HIV-1 persistence following early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med 2017; 14: e1002417.